Journal Article

Genetic Testing is Superior Over Endogenous Pharmacometabolomic Markers to Predict Safety of Haloperidol in Patients with Alcohol-induced Psychotic Disorder

  • Skryabin V
  • Zastrozhin M
  • Parkhomenko A
  • et al.
Current Drug Metabolism (2022) 23(13) 1067-1071
DOI: 10.2174/1389200224666221228112643
2Citations
Citations of this article
N/AReaders
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Skryabin, V., Zastrozhin, M., Parkhomenko, A., Lauschke, V. M., Smirnov, V., Petukhov, A., … Sychev, D. (2022). Genetic Testing is Superior Over Endogenous Pharmacometabolomic Markers to Predict Safety of Haloperidol in Patients with Alcohol-induced Psychotic Disorder. Current Drug Metabolism, 23(13), 1067–1071. https://doi.org/10.2174/1389200224666221228112643

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free